Johns Hopkins University

Magdalena Scully

Seulki Lee

Martin Gilbert Pomper

Ted M Dawson

Valina L Dawson

Han Seok Ko

Seung Pil Yun

Pankaj Jay Pasricha

Jong-Sung Park

Yumin Oh

Maureen Horton

Ogyi Park

The present invention relates to compositions and methods for treating neurodegenerative conditions using GLP-1r agonists. In certain embodiments, long-acting GLP-1r agonists have neuroprotective and disease modifying effects on the central nervous system.

Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions

Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions

Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibodies. In certain embodiments, TRAIL analogs and anti-death receptor 5 agonistic antibodies have analgesic and disease modifying effects on the pancreas.

Compositions and methods for treating pancreatitis and pain with death receptor agonists

The present disclosure relates to methods and compositions for treating and/or preventing autoimmune fibrosis, such as systemic sclerosis (SSc; scleroderma). The method includes administering to a subject in need thereof an effective amount of a death receptor agonist. Suitable death receptor agonists include tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), agonistic death receptor antibodies, and variants, analogues, or derivatives thereof. The administration of the death receptor agonist blocks fibroblast or profibrogenic cell activation, and/or reduces or depletes myofibroblasts, thereby reducing or preventing systemic sclerosis.

Ameliorating systemic sclerosis with death receptor agonists

Growing community of inventors

Columbia, MD, United States of America

Magdalena Scully